Home » Stocks » Novavax

Novavax, Inc. (NVAX)

Stock Price: $87.38 USD -5.75 (-6.17%)
Updated Oct 26, 2020 4:00 PM EDT - Market closed
After-hours: $88.02 +0.64 (0.73%) Oct 26, 7:59 PM

Stock Price Chart

Key Info

Market Cap 5.35B
Revenue (ttm) 50.24M
Net Income (ttm) -93.26M
Shares Out 61.28M
EPS (ttm) -2.40
PE Ratio n/a
Forward PE 3.32
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 26, 2020
Last Price $87.38
Previous Close $93.13
Change ($) -5.75
Change (%) -6.17%
Day's Open 91.03
Day's Range 86.53 - 94.23
Day's Volume 2,759,176
52-Week Range 3.54 - 189.40

More Stats

Market Cap 5.35B
Enterprise Value 5.07B
Earnings Date (est) Nov 4, 2020
Ex-Dividend Date n/a
Shares Outstanding 61.28M
Float 61.00M
EPS (basic) -2.70
EPS (diluted) -2.40
FCF / Share 0.55
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield 0.60%
Payout Ratio n/a
Shares Short 7.82M
Short Ratio 1.39
Short % of Float 12.82%
Beta 1.39
PE Ratio n/a
Forward PE 3.32
P/FCF Ratio 167.00
PS Ratio 106.58
PB Ratio 30.93
Revenue 50.24M
Operating Income -83.62M
Net Income -93.26M
Free Cash Flow 32.06M
Net Cash 288.15M
Net Cash / Share 4.70
Gross Margin -189.46%
Operating Margin -166.44%
Profit Margin -185.60%
FCF Margin 63.82%
ROA -10.32%
ROE -93.79%
ROIC -22.20%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (5)

Buy 3
Overweight 0
Hold 2
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$220.80*
(152.69% upside)
Low
105
Current: $87.38
High
290
Target: 220.80
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue18.6634.2931.1815.3536.2530.6620.9222.0814.690.34
Revenue Growth-45.57%9.98%103.06%-57.65%18.24%46.59%-5.26%50.3%4182.22%-
Gross Profit18.6634.2931.1815.3536.2530.6620.927.387.690.34
Operating Income-121-174-172-269-157-83.69-52.43-29.67-21.58-38.49
Net Income-133-185-184-280-157-82.95-51.98-28.51-19.36-35.71
Shares Outstanding24.1018.4914.6313.5413.1111.298.486.595.685.24
Earnings Per Share-5.51-9.99-12.56-20.60-12.00-7.40-6.20-4.40-3.40-6.80
Operating Cash Flow-137-185-144-259-126-67.01-45.36-18.23-23.63-32.85
Capital Expenditures-1.86-1.37-4.19-18.20-18.27-7.23-5.67-4.02-0.61-1.56
Free Cash Flow-138-186-149-277-144-74.24-51.03-22.25-24.24-34.41
Cash & Equivalents82.1810418627026816813445.8518.3131.68
Total Debt3213193183160.401.001.881.210.320.40
Net Cash / Debt-238-215-131-45.9626816713344.6517.9931.28
Assets17320830239438627623510266.5874.84
Liabilities35937640440093.3746.3831.8922.1112.7315.79
Book Value-186-168-102-5.5529323020380.2453.8559.05
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Novavax, Inc.
Country United States
Employees 359
CEO Stanley C. Erck

Stock Information

Ticker Symbol NVAX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: NVAX
IPO Date December 5, 1995

Description

Novavax, together with its subsidiary, Novavax AB, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. The company's lead vaccine candidates include ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate that in Phase III clinical trial to protect infants from RSV disease through maternal immunization; and NanoFlu, which is in Phase III clinical trial for treating seasonal influenza in older adults. Its lead adjuvant is Matrix-M that is used to enable a vaccine to enhance the amplitude of the immune response and qualitatively change it, and the immune systems attack against microorganisms, as well as to allow immunization with much lower doses of antigen. The company is also developing RSV F vaccine for older adults (60 years and older) that is in Phase II clinical trial, as well as for healthy children between six months to five years of age that is in Phase I clinical trial. In addition, it develops nanoparticle vaccine candidates for clinic testing against ebola virus that is in Phase I clinical trial; and combination respiratory vaccine to protect against influenza and RSV. Further, the company is developing COVID-19 vaccine for coronavirus that causes pneumonia-like symptoms, which is in preclinical stage. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.